PharmExec Direct:
Having trouble viewing this e-mail? Click here.
PharmExec Direct | From the editors of Pharmaceutical Executive Visit the PharmExec website
 
Send Us Some Feedback
| Update My Profile | Advertise With Us | Visit PharmExec.com |
PRINT SUBSCRIBE | DIGITAL SUBSCRIBE
November 20, 2014 | ISSUE NUMBER 378 VOL 4

Open Payments
CMS Struggles to Fix Sunshine System
The feds have "a long way to go" to get the Open Payments system operating effectively and user friendly. Doug Brown, acting director of the Data Sharing & Partnership Group at the Center for Program Integrity, explained at this month's Pharmaceutical Regulatory and Compliance Congress what needs to be done ...Read more

Events
Health 2.0: HCP Apps Steal the Show
Two of the industry's most influential conferences — TEDMED (Washington, DC) and Health 2.0 (San Francisco, CA) — occurred within weeks of each other this autumn. Pharm Exec Editorial Advisory Board member Bill Drummy was at both events and found the major trends easy to see ...Read more

Europe
Guido Rasi's EMA Exit: No-one's in Charge of Pharmaceuticals in Europe!
Last week’s story by Peter O’Donnell — Who’s in charge of Medicines in Brussels? — has been overtaken by history with the departure of Guido Rasi from his post of Executive Director of the European Medicines Agency. At a time of flux in the European context for pharmaceuticals, Rasi’s moderate manner and capacity for strategic thinking will be missed ...Read more

Europe
EU Edges Toward a New HTA Understanding
The European Union is moving ahead, in its own slightly crabwise fashion, with its attempts to work out what healthcare budgets should be used for. It has been flirting with health technology assessment (HTA) for some time now, but for a long while the relationship was conducted in the EU's usual hands-off "don't look at me while I'm doing this" approach to pharmaceuticals and money. Reflector reports ...Read more

Special Feature
Pharm Exec's 2015 Pipeline Report
This year's pipeline report checks in on the emerging technologies, as well as potential therapies to address metabolic and neurodegenerative diseases. There's a lot to like in the pipeline and more than a little competitive drama to make it really interesting. But is pharma ready to raise its game and cut a deal with all those "prove it to me" payers? ...Read more

//Catabasis Pharmaceuticals (Cambridge, MA) named Angelika Fretzen, Ph.D., as Vice President of Development.//Antares Pharma (Ewing, NJ) announced the appointment of James E. Fickenscher to the position of Senior Vice President, Chief Financial Officer.//Bellicum Pharmaceuticals (Houston, TX) appointed Reid M. Huber, Ph.D. to its Board of Directors. //Intercept Pharmaceuticals (New York, NY, and London, UK) named Lisa Bright as Senior Vice President and Head of Europe.//

January 29–30, 2015: 10th Annual Summit on Biosimilars Washington, DC
Washington, DC


February 24–25, 2015: Oncology Commercialization and Market Access
San Francisco, CA


February 25–26: Speaker Programs 2015
Philadelphia, PA



 
Follow Pharm Exec on Twitter
Follow Pharm Exec on Facebook
Follow Pharm Exec on Linkedin

Survey
Which of the following is your most important upcoming initiative?
Click To Vote

Quick Links

The Top Medical Innovations for 2015

Medicare Part B Data: Handle with Care

Merck KGaA CEO Raises Ire on IP and Access to Medicines

Pharm Exec eBooks Available as Apps